Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.
暂无分享,去创建一个
T. Boggon | M. Eck | P. Manley | Yiqun Li | Michael J Eck | Paul W Manley | Titus J Boggon | Yiqun Li
[1] S V Evans,et al. SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. , 1993, Journal of molecular graphics.
[2] J. Kuriyan,et al. The Conformational Plasticity of Protein Kinases , 2002, Cell.
[3] Eugene C. Petrella,et al. The Three-dimensional Structure of the ZAP-70 Kinase Domain in Complex with Staurosporine , 2004, Journal of Biological Chemistry.
[4] L. Toledo,et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. , 2000, Structure.
[5] A. Verma,et al. Jak family of kinases in cancer , 2003, Cancer and Metastasis Reviews.
[6] K Imada,et al. The Jak-STAT pathway. , 2000, Molecular immunology.
[7] S. Rane,et al. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. , 1994, Oncogene.
[8] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[9] B. Mroczkowski,et al. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. , 1999, Structure.
[10] Stevan R. Hubbard,et al. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase , 2001, Nature Structural Biology.
[11] John Kuriyan,et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.
[12] A. Papageorgiou,et al. Is JAK3 a new drug target for immunomodulation-based therapies? , 2004, Trends in pharmacological sciences.
[13] M. Säemann,et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor , 2004, European Surgery.
[14] L. Notarangelo,et al. Eleven novel JAK3 mutations in patients with severe combined immunodeficiency—including the first patients with mutations in the kinase domain , 2001, Human mutation.
[15] J. O’Shea,et al. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[16] P. Rothman,et al. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. , 1997, Journal of immunology.
[17] V S Lamzin,et al. Automated refinement for protein crystallography. , 1997, Methods in enzymology.
[18] Takamune Takahashi,et al. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases , 1994, FEBS letters.
[19] J. Thornton,et al. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.
[20] A. W. Schüttelkopf,et al. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.
[21] Á. Carracedo,et al. Mutation analysis of the adenomatous polyposis coli (APC) gene in northwest Spanish patients with familial adenomatous polyposis (FAP) and sporadic colorectal cancer , 2001, Human mutation.
[22] S. Hubbard. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.
[23] M. Vihinen,et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency , 2001, Human mutation.
[24] C. Sawyers,et al. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. , 1996, Oncogene.
[25] J. Johnston,et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[26] S. Rane,et al. Janus kinases: components of multiple signaling pathways , 2000, Oncogene.
[27] R Berger,et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.
[28] O. Silvennoinen,et al. Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain , 2000, Molecular and Cellular Biology.
[29] R J Read,et al. Pushing the boundaries of molecular replacement with maximum likelihood. , 2003, Acta crystallographica. Section D, Biological crystallography.
[30] Hiroto Yamaguchi,et al. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.
[31] J. O’Shea,et al. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. , 2004, Blood.
[32] J. Zheng,et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.
[33] J. Puck,et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. , 1997, The Journal of pediatrics.
[34] K. K. Jacob,et al. Insulin receptor tyrosine kinase activity and phosphorylation of tyrosines 1162 and 1163 are required for insulin-increased prolactin gene expression , 2002, Molecular and Cellular Endocrinology.
[35] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[36] L. Lally. The CCP 4 Suite — Computer programs for protein crystallography , 1998 .
[37] N. Danial,et al. Jak-STAT signaling induced by the v-abl oncogene. , 1995, Science.
[38] J. O’Shea,et al. A new modality for immunosuppression: targeting the JAK/STAT pathway , 2004, Nature Reviews Drug Discovery.
[39] J. O’Shea,et al. Jak3 and the pathogenesis of severe combined immunodeficiency. , 2004, Molecular immunology.